Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension

Wang,Yugang; Dong,Jinbin; Meng,Wenying; Ma,Jiali; Wang,Na; Wei,Jue; Shi,Min

doi:10.3892/ijmm.2014.1662

Effects of phased joint intervention on IL-35 and IL-17 expression levels in patients with portal hypertension

Authors:
- Yugang Wang
- Jinbin Dong
- Wenying Meng
- Jiali Ma
- Na Wang
- Jue Wei
- Min Shi
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Changning Central Hospital, Shanghai 200336, P.R. China
Published online on: February 19, 2014 https://doi.org/10.3892/ijmm.2014.1662
Pages: 1131-1139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the clinical efficacy of phased joint intervention [percutaneous transhepatic variceal embolization (PTVE) + phased partial splenic embolization (PSE)] in patients with portal hypertension complicated by esophageal variceal bleeding and hypersplenism and the effect of this intervention on interleukin-35 (IL-35)/IL-17 expression. A review of 53 patients with portal hypertension caused by liver cirrhosis and complicated by esophageal variceal bleeding and hypersplenism treated with phased joint intervention was conducted, and portal hemodynamics, routine blood examinations and liver function were determined. Quantitative polymerase chain reaction (qPCR) was used to evaluate EBI3, FOXP3 and IL-17 mRNA expression levels in peripheral blood mononuclear cells (PBMC) before and after the phased joint intervention, while western blot analysis was used to determine their protein expression. All 53 patients required emergency hemostasis resulting in an emergency hemostatic rate of 100%. Varicose veins disappeared, portal hemodynamics and liver function improved subsequent to the intervention. The expression levels of EBI3, FOXP3 and IL-17 mRNA in the postoperative group were significantly lower than the preoperative levels (P<0.01). The protein expression levels of EBI3, FOXP3 and IL-17 in the postoperative group were reduced compared with the preoperative levels. The concentrations of IL-35, IL-6 and IL-17 in peripheral blood were significantly reduced after the phased joint intervention (P<0.01). Serum IL-35, IL-6 and IL-17 levels were positively correlated with total bilirubin and international normalized ratio, and negatively correlated with albumin. The phased joint intervention can effectively treat esophageal variceal bleeding and hypersplenism, and improve liver function. The efficacy of this intervention may be associated with the regulation of immune function.

View Figures

View References

1	Comar KM and Sanyal AJ: Portal hypertensive bleeding. Gastroenterol Clin North Am. 32:1079–1105. 2003. View Article : Google Scholar
2	Augustin S, González A and Genescà J: Acute esophageal variceal bleeding: Current strategies and new perspectives. World J Hepatol. 2:261–274. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kovalak M, Lake J, Mattek N, Eisen G, Lieberman D and Zaman A: Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointest Endosc. 65:82–88. 2007. View Article : Google Scholar : PubMed/NCBI
4	Groszmann RJ, Garcia-Tsao G, Bosch J, et al: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. The N Engl J Med. 353:2254–2261. 2005. View Article : Google Scholar : PubMed/NCBI
5	Merli M, Nicolini G, Angeloni S, et al: Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 38:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
6	D’Amico G, Pagliaro L and Bosch J: Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 19:475–505. 1999.PubMed/NCBI
7	Bosch J and Garcia-Pagan JC: Prevention of variceal rebleeding. Lancet. 361:952–954. 2003. View Article : Google Scholar
8	de Franchis R: Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 43:167–176. 2005.
9	Lunderquist A and Vang J: Sclerosing injection of esophageal varices through transhepatic selective catheterization of the gastric coronary vein. A preliminary report. Acta Radiol Diagn (Stockh). 15:546–550. 1974.
10	Benner KG, Keeffe EB, Keller FS and Rösch J: Clinical outcome after percutaneous transhepatic obliteration of esophageal varices. Gastroenterology. 85:146–153. 1983.PubMed/NCBI
11	Chikamori F, Kuniyoshi N, Shibuya S and Takase Y: Correlation between endoscopic and angiographic findings in patients with esophageal and isolated gastric varices. Dig Surg. 18:176–181. 2001. View Article : Google Scholar : PubMed/NCBI
12	L’Hermine C, Chastanet P, Delemazure O, Bonniere PL, Durieu JP and Paris JC: Percutaneous transhepatic embolization of gastroesophageal varices: results in 400 patients. AJR Am J Roentgenol. 152:755–760. 1989.PubMed/NCBI
13	Koconis KG, Singh H and Soares G: Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol. 18:463–481. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shi Y, Wang Y, Shi M, et al: Clinical study of combined interventional treatment of portal hypertension. Chin J Ethnomed Ethnopharm. 11:63–65. 2010.(In Chinese).
15	Henderson NC and Iredale JP: Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond). 112:265–280. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wang J, Leclercq I, Brymora JM, et al: Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology. 137:713–723. 2009. View Article : Google Scholar : PubMed/NCBI
17	Pesce JT, Ramalingam TR, Mentink-Kane MM, et al: Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 5:e10003712009. View Article : Google Scholar : PubMed/NCBI
18	Gao B, Radaeva S and Park O: Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 86:513–528. 2009.PubMed/NCBI
19	Delhem N, Carpentier A, Morales O, et al: Regulatory T-cells and hepatocellular carcinoma: implication of the regulatory T lymphocytes in the control of the immune response. Bull Cancer. 95:1219–1225. 2008.(In French).
20	Delhem N, Cottrez F, Carpentier A, et al: Role of the regulatory T lymphocytes in hepatitis C fibrosis progression. Bull Cancer. 95:1029–1038. 2008.(In French).
21	Moriyasu F, Nishida O, Ban N, et al: Measurement of portal vascular resistance in patients with portal hypertension. Gastroenterology. 90:710–717. 1986.PubMed/NCBI
22	Scott J, Dick R, Long RG and Sherlock S: Percutaneous transhepatic obliteration of gastro-oesophageal varices. Lancet. 2:53–55. 1976. View Article : Google Scholar : PubMed/NCBI
23	Sangro B, Bilbao I, Herrero I, et al: Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology. 18:309–314. 1993. View Article : Google Scholar : PubMed/NCBI
24	Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lunderquist A and Owman T: Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg. 196:518–524. 1982. View Article : Google Scholar : PubMed/NCBI
25	Moro E, Pais M, Benvegnu M, Ferrari M and Bittolo Bon G: Decrease of insulin resistance after splenectomy in a diabetic patient with liver cirrhosis and portal hypertension. Physiopathologic evaluation. Minerva Gastroenterol Dietol. 40:213–218. 1994.(In Italian).
26	Pålsson B, Hallén M, Forsberg AM and Alwmark A: Partial splenic embolization: long-term outcome. Langenbecks Arch Surg. 387:421–426. 2003.PubMed/NCBI
27	Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N and Kumazaki T: Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology. 49:1445–1448. 2002.PubMed/NCBI
28	Yamaguchi S, Kawanaka H, Yoshida D, Maehara Y and Hashizume M: Splenic hemodynamics and decreased endothelial nitric oxide synthase in the spleen of rats with liver cirrhosis. Life Sci. 80:2036–2044. 2007. View Article : Google Scholar : PubMed/NCBI
29	Hoefs JC, Wang FW, Lilien DL, Walker B and Kanel G: A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nucl Med. 40:1745–1755. 1999.PubMed/NCBI
30	Chadburn A: The spleen: anatomy and anatomical function. Semin Hematol. 37(Suppl 1): S13–S21. 2000. View Article : Google Scholar
31	Okamoto A, Fujio K, van Rooijen N, et al: Splenic phagocytes promote responses to nucleosomes in (NZB × NZW) F1 mice. J Immunol. 181:5264–5271. 2008.PubMed/NCBI
32	Sekiguchi T, Nagamine T, Takagi H and Mori M: Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol. 12:1205–1210. 2006.PubMed/NCBI
33	Li ZF, Zhang S, Lv GB, et al: Changes in count and function of splenic lymphocytes from patients with portal hypertension. World J Gastroenterol. 14:2377–2382. 2008. View Article : Google Scholar : PubMed/NCBI
34	Harrington LE, Hatton RD, Mangan PR, et al: Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005.PubMed/NCBI
35	Infante-Duarte C, Horton HF, Byrne MC and Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 165:6107–6115. 2000. View Article : Google Scholar : PubMed/NCBI
36	Park H, Li Z, Yang XO, et al: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
37	Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS and Jia JH: Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat. 19:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
38	Lemmers A, Moreno C, Gustot T, et al: The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 49:646–657. 2009. View Article : Google Scholar : PubMed/NCBI
39	Wang L, Chen S and Xu K: IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int J Mol Med. 27:385–392. 2011.PubMed/NCBI
40	Ye Y, Xie X, Yu J, et al: Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol. 30:546–555. 2010. View Article : Google Scholar : PubMed/NCBI
41	Li H, Zheng HW, Chen H, et al: Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokines. Dig Liver Dis. 44:328–333. 2012.PubMed/NCBI
42	Bettelli E, Carrier Y, Gao W, et al: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar
43	Mangan PR, Harrington LE, O’Quinn DB, et al: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231–234. 2006. View Article : Google Scholar
44	Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
45	Niedbala W, Wei XQ, Cai B, et al: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 37:3021–3029. 2007. View Article : Google Scholar : PubMed/NCBI
46	Collison LW, Chaturvedi V, Henderson AL, et al: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
47	Yang J, Yang M, Htut TM, et al: Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol. 38:1204–1214. 2008. View Article : Google Scholar : PubMed/NCBI
48	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
49	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
50	Khattri R, Cox T, Yasayko SA and Ramsdell F: An essential role for Scurfin in CD4⁺CD25⁺ T regulatory cells. Nat Immunol. 4:337–342. 2003. View Article : Google Scholar : PubMed/NCBI